IP Library › Granted Patent US 7,148,343
Granted Patent B2
US 7,148,343 · App. 10/418,194 · Granted Dec 12, 2006

Compositions and methods for using a solid support to purify RNA

Assignee: Gentra Systems, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,148,343
App. No.
10/418,194
Granted
Dec 12, 2006
Kind
B2
Abstract

Reagents, methods and kits for the purification of RNA from biological materials are provided.

Claims (26)

1. A formulation for isolating and purifying nucleic acids comprising:

a lithium salt at a concentration of about 4–10 M, a detergent, and a buffer, wherein the formulation has a pH above about 7 and lacks a chaotrope.

2. The formulation of claim 1 , further comprising a chelating agent.

3. The formulation of claim 1 , further comprising a reducing agent.

4. The formulation of claim 1 , wherein the lithium salt is lithium chloride.

5. The formulation of claim 1 , wherein the solution has a pH between about 7 and about 9.

6. The formulation of claim 1 , wherein the detergent is an anionic, cationic, zwitterionic or non-ionic detergent.

7. The formulation of claim 6 , wherein the detergent is a non-ionic detergent.

8. The formulation of claim 7 , wherein the detergent is a tween, triton, nonidet, igepal or tergitol.

9. The formulation of claim 1 , wherein the detergent is a mixture of triton-x and diethyl glycol monoethyl ether (DGME).

10. The formulation of claim 1 , wherein the detergent is a mixture of 5% v/v triton-x and 5% v/v DGME.

11. The formulation of claim 1 , wherein the detergent is present at a concentration of about 10% v/v of the final volume of the solution.

12. The formulation of claim 1 , wherein the buffer has a pKa of at least about 8.

13. The formulation of claim 1 , wherein the chelating agent is EDTA.

14. The formulation of claim 1 , wherein the reducing agent is Tris (carboxyethyl) phosphine (TCEP).

15. The formulation of claim 1 , further comprising a tungstate.

16. An article of manufacture for isolating and purifying nucleic acids comprising:

the formulation of claim 1 ; and

a solid support.

17. The formulation of claim 1 , further comprising a surfactant.

18. The formulation of claim 17 , wherein the surfactant is DGME.

19. A formulation for isolating and purifying nucleic acids comprising:

a lithium salt at a concentration of about 4–10 M, a detergent, and a buffer, wherein the formulation has a pH below about 4.5 and lacks a chaotrope.

20. An article of manufacture for isolating and purifying nucleic acids, comprising:

the formulation of claim 19 ; and

a solid support.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2007
From: GENTRA SYSTEMS INC.
To: QIAGEN NORTH AMERICAN HOLDINGS, INC
Reel/Frame 019241/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2003
From: BAIR JR., ROBERT JACKSON; HEATH, ELLEN M.; MEEHAN, HEATHER; PAULSEN, KIM ELAYNE; WAGES JR., JOHN M.
To: GENTRA SYSTEMS, INC.
Reel/Frame 014476/0324 →
Continuity (2)
Continuation In Part 0997479800 · Oct 12, 2001
Related Publication 20040019196A1 · Jan 29, 2004